SAFE-BioPharma Selects Verizon to Manage Digital Identity Services

Verizon is Now Supporting SAFE-BioPharma(R) Standard for Its Universal Identity Services for Healthcare

NEW YORK & FORT LEE, N.J., Jun 21, 2011 (BUSINESS WIRE) -- SAFE-BioPharma Association and Verizon today announced that they have entered into an agreement in which Verizon will manage the association's digital identity services and issue SAFE-BioPharma digital credentials to its members.

As part of the agreement, Verizon will provide SAFE-BioPharma's proprietary Registration Authority System (RAS) service directly to SAFE-BioPharma Association members. RAS is a rapid, online identity-proofing and certificate issuance system used to establish verifiable individual identities and to provide digital credentials for online use.

In addition, Verizon is now supporting the SAFE-BioPharma standard in its Universal Identity Services for Healthcare (credentials used by health care workers to universally access health IT information securely) to help address biopharmaceutical and health care sector concerns about cybersecurity, interoperability, and regulatory compliance. This standard enables SAFE BioPharma Association members and other health care organizations to use digital signatures for processing electronic documents such as insurance reimbursement and clinical research, as well as prescribe medications, including controlled substances, electronically.

"Verizon has the depth, expertise and resources to successfully manage our digital identity services," said Mollie Shields-Uehling, president and CEO, SAFE BioPharma Association. "These services help mitigate risk inherent in electronic transactions within the biopharmaceutical and health care industries."

The SAFE-BioPharma standard is the only solution designed specifically for the life sciences and to offer a secure level of strong identity trust and validation, as well as the only life science digital standard that provides for interoperability with government agencies, such as the U.S. Food and Drug Administration and the European Medicines Agency. Use of the standard requires membership in SAFE-BioPharma Association.

"Verizon is committed to advancing health care through the use of information technology," said Peter Tippett M.D., vice president, industry solutions and security services, Verizon Business. "By enabling widespread distribution of SAFE-BioPharma digital credentials, Verizon is one step closer to helping healthcare organizations unlock the potential of health IT."

About SAFE-BioPharma

SAFE-BioPharma is the global industry standard for digital trust. It was developed by a non-profit consortium of biopharmaceutical and related companies to transition the biopharmaceutical and health care communities to paperless environments. For more information visit:

SAFE-BioPharma(R) is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.

About Verizon

Verizon Communications Inc. (NYSE, NASDAQ:VZ), headquartered in New York, is a global leader in delivering broadband and other wireless and wireline communications services to mass market, business, government and wholesale customers. Verizon Wireless operates America's most reliable wireless network, with more than 104 million total connections nationwide. Verizon also provides converged communications, information and entertainment services over America's most advanced fiber-optic network, and delivers seamless business solutions to customers around the world. A Dow 30 company, Verizon employs a diverse workforce of more than 196,000 and last year generated consolidated revenues of $106.6 billion. For more information, visit .

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.